Colombatti Raffaella, Hegemann Inga, Medici Morten, Birkegård Camilla
Clinic of Pediatric Hematology Oncology, Department of Child and Maternal Health, Azienda Ospedaliera, University of Padova, 35122 Padua, Italy.
Novo Nordisk Pharma AG, 8058 Zürich, Switzerland.
J Clin Med. 2023 Aug 25;12(17):5538. doi: 10.3390/jcm12175538.
Sickle cell disease (SCD) is an inherited monogenic disorder with high prevalence throughout sub-Saharan Africa, the Mediterranean basin, the Middle East, and India. Sources of SCD epidemiology remain scarce and fragmented. A systematic literature review (SLR) to identify peer-reviewed studies on SCD epidemiology was performed, with a search of bibliographic databases and key conference proceedings from 1 January 2010 to 25 March 2022 (congress abstracts after 2018). The SLR followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Meta-analyses, using a binomial normal random-effects model, were performed to estimate global and regional prevalence and birth prevalence. Of 1770 journal articles and 468 abstracts screened, 115 publications met the inclusion criteria. Prevalence was highest in Africa (800/100,000), followed by the Middle East (200/100,000) and India (100/100,000), in contrast to ~30/100,000 in Europe. Birth prevalence was highest in Africa (1000/100,000) and lowest in North America (50/100,000) and Europe (30/100,000). This SLR confirmed that sub-Saharan and North-East Africa, India, the Middle East, and the Caribbean islands are global SCD hotspots. Publications including mortality data were sparse, and no conclusions could be drawn about mortality. The identified data were limited due to gaps in the published literature for large parts of the world population; the inconsistent reporting of SCD genotypes, diagnostic criteria, and settings; and a sparsity of peer-reviewed publications from countries with assumed high prevalence. This SLR demonstrated a lack of systematic knowledge and a need to provide uniform data collection on SCD prevalence and mortality.
镰状细胞病(SCD)是一种遗传性单基因疾病,在撒哈拉以南非洲、地中海盆地、中东和印度等地广泛流行。SCD流行病学的资料仍然稀缺且零散。我们进行了一项系统文献综述(SLR),以识别关于SCD流行病学的同行评审研究,检索了2010年1月1日至2022年3月25日的书目数据库和关键会议记录(2018年后的会议摘要)。该SLR遵循PRISMA(系统评价和Meta分析的首选报告项目)指南。采用二项式正态随机效应模型进行Meta分析,以估计全球和区域患病率以及出生患病率。在筛选的1770篇期刊文章和468篇摘要中,115篇出版物符合纳入标准。患病率在非洲最高(约800/10万),其次是中东(约200/10万)和印度(约100/10万),而欧洲约为30/10万。出生患病率在非洲最高(约1000/10万),在北美(约50/10万)和欧洲(约30/10万)最低。该SLR证实,撒哈拉以南和东北非洲、印度、中东和加勒比群岛是全球SCD热点地区。包含死亡率数据的出版物很少,无法得出关于死亡率的结论。由于世界大部分人口的已发表文献存在空白、SCD基因型、诊断标准和环境的报告不一致,以及假定患病率高的国家的同行评审出版物稀少,所确定的数据有限。该SLR表明缺乏系统的知识,需要提供关于SCD患病率和死亡率的统一数据收集。